← Leaderboards
Jun J. Yang
St. Jude Children'S Research Hospital
$13,116,250
Attributed
$19,496,206
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.2M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,496,206 · 10
By mechanism
R01$10,385,853 · 4
U01$5,142,009 · 2
R35$2,872,000 · 1
R21$421,889 · 1
R03$374,456 · 1
R56$299,999 · 1
Top collaborators
- Jiyang Yu6 shared
- David T. Teachey5 shared
- Kim Erika Nichols2 shared
- Mignon Lee-Cheun Loh1 shared
- Philip Lupo1 shared
- Sarah Kathleen Tasian1 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Mary V. Relling$28,942,987
- Charles G. Mullighan$25,123,215
- Joseph T. Opferman$6,361,955
- William E. Evans$20,051,064
- Camenzind G Robinson$1,336,779
Others in their field
Top investigators on “Leukemia”
- Richard K. Wilson · Washington University$209,620,938
- David Heimbrook · Leidos Biomedical Research, Inc.$168,419,678
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Peter C Adamson · National Childhood Cancer Foundation$143,910,899
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Richard L Schilsky · University Of Chicago$129,102,207
Research focus
LeukemiaPharmaceutical PreparationsChildResponseGenesVariantGeneticAcute Lymphocytic LeukemiaRelapseGenomicsMalignant Childhood NeoplasmChildhood LeukemiaClinical TrialsSamplingPositioning AttributeCellsCytotoxicityMalignant NeoplasmsMolecularBaseTreatment ResponseReportingResearch PersonnelPharmacology
Grant awards (35)
Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia$3,480,276
R01 · FY2025 · CA
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia$599,172
R01 · FY2025 · CA · contact PI
Pharmacogenetics of Nucleobase and Nucleoside Analog Drugs$574,400
R35 · FY2025 · GM · contact PI
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia$528,622
U01 · FY2025 · CA
Pharmacogenetics of Nucleobase and Nucleoside Analog Drugs$574,400
R35 · FY2024 · GM · contact PI
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia$569,213
R01 · FY2024 · CA · contact PI
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia$501,244
U01 · FY2024 · CA
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia$587,189
R01 · FY2023 · CA · contact PI
Pharmacogenetics of Nucleobase and Nucleoside Analog Drugs$574,400
R35 · FY2023 · GM · contact PI
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia$518,050
U01 · FY2023 · CA
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia$700,050
U01 · FY2022 · CA
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia$587,189
R01 · FY2022 · CA · contact PI
Pharmacogenetics of Nucleobase and Nucleoside Analog Drugs$574,400
R35 · FY2022 · GM · contact PI
Effects of germline GATA3 variants on ALL somatic genomics and prognosis in multi-ethnic populations$299,999
R56 · FY2022 · CA · contact PI
Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia$619,047
R01 · FY2021 · CA · contact PI
Pharmacogenetics of Nucleobase and Nucleoside Analog Drugs$574,400
R35 · FY2021 · GM · contact PI
Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia$528,622
U01 · FY2021 · CA
Pathogenesis of ETV6-Related Acute Lymphoblastic Leukemia$1,506,693
R01 · FY2020 · CA
Genetics-guided Individualization of Thiopurine Therapy$549,331
R01 · FY2020 · GM · contact PI
Systems biology analyses to identify driver genes in Down syndrome-related ALL$374,456
R03 · FY2020 · HD · contact PI
Pathogenesis of ETV6-Related Acute Lymphoblastic Leukemia$199,999
R01 · FY2020 · CA
Genetics-guided Individualization of Thiopurine Therapy$549,331
R01 · FY2019 · GM · contact PI
Genetics-guided Individualization of Thiopurine Therapy$558,496
R01 · FY2018 · GM · contact PI
ARID5B and disparities of childhood leukemia$368,510
U01 · FY2018 · CA · contact PI
Genetics-guided Individualization of Thiopurine Therapy$579,917
R01 · FY2017 · GM · contact PI
ARID5B and disparities of childhood leukemia$368,510
U01 · FY2017 · CA · contact PI
ARID5B and disparities of childhood leukemia$99,290
U01 · FY2017 · CA · contact PI
ARID5B and disparities of childhood leukemia$365,074
U01 · FY2016 · CA · contact PI
ARID5B and disparities of childhood leukemia$199,999
U01 · FY2016 · CA · contact PI
ARID5B and disparities of childhood leukemia$99,152
U01 · FY2016 · CA · contact PI
ARID5B and disparities of childhood leukemia$377,891
U01 · FY2015 · CA · contact PI
ARID5B and disparities of childhood leukemia$98,461
U01 · FY2015 · CA · contact PI
ARID5B and disparities of childhood leukemia$388,534
U01 · FY2014 · CA · contact PI
PDE4B and pharmacoethnicity of childhood leukemia$182,916
R21 · FY2012 · CA · contact PI
PDE4B and pharmacoethnicity of childhood leukemia$238,973
R21 · FY2011 · CA · contact PI